Opportunities and challenges for human papillomavirus vaccination in China

• Published in: Human vaccines & immunotherapeutics Vol. 20; no. 1; p. 2329450
• Main Authors: Zhao, Chao, Zhao, Yun, Li, Jingran, Li, Mingzhu, Shi, Yujing, Wei, Lihui
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis Group 31-12-2024
• Subjects: attitudes; Cervical cancer; human papillomavirus; knowledge; long-term efficacy; vaccination; long-term efficacy; attitudes; human papillomavirus; Cervical cancer; practices; knowledge; vaccination
• ISSN: 2164-5515; 2164-554X; 2164-554X
• DOI: 10.1080/21645515.2024.2329450

Current estimates of the HPV infection rate in China vary by geographic region (9.6-23.6%), with two age peaks in prevalence in women ≤20-25 years of age and 50-60 years of age. HPV-16, 52 and 58 are the most commonly-detected HPV genotypes in the Chinese population. In China, five HPV vaccines are licensed and several others are undergoing clinical trials. Multiple RCTs have shown the efficacy and safety of the bvHPV (Cervarix),
-produced bvHPV (Cecolin),
-produced bvHPV (Walrinvax), qvHPV (Gardasil) and 9vHPV (Gardasil-9) vaccines in Chinese populations, including two studies showing long-term efficacy (≥8 years) for the bvHPV and qvHPV vaccines. Real-world data from China are scarce. Although modeling studies in China show HPV vaccination is cost-effective, uptake and population coverage are relatively low. Various policies have been implemented to raise awareness and increase vaccine coverage, with the long-term aim of eliminating cervical cancer in China.